Troxerutin subdues hepatic tumorigenesis via disrupting the MDM2–p53 interaction

2018 ◽  
Vol 9 (10) ◽  
pp. 5336-5349 ◽  
Author(s):  
Nisha Susan Thomas ◽  
Kiran George ◽  
Athavan Alias Anand Selvam
Keyword(s):  
Hepatocellular Carcinoma ◽  
Common Cause ◽  
The Third ◽  
Common Cancer ◽  
Hepatic Tumorigenesis

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of mortality worldwide.

scholarly journals Abdominal Ultrasound and Treatment of Hepatocellular Carcinoma

Diagnostics ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 1268
Author(s):  
Kazushi Numata
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Abdominal Ultrasound ◽  
Cancer Death ◽  
Common Cause ◽  
Cancer Statistics ◽  
The Third ◽  
Common Cancer

Liver cancer is the sixth most common cancer and the third most common cause of cancer death, based on Global Cancer Statistics 2020 [...]

scholarly journals Extracellular Vesicles, A Possible Theranostic Platform Strategy for Hepatocellular Carcinoma—An Overview

Cancers ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 261 ◽  
Author(s):  
Igea D’Agnano ◽  
Anna Concetta Berardi
Keyword(s):  
Hepatocellular Carcinoma ◽  
Targeted Drug Delivery ◽  
Kinase Inhibitors ◽  
Standard Treatment ◽  
Extracellular Vesicle ◽  
Great Promise ◽  
The Third ◽  
Common Cancer ◽  
Targeted Drug ◽  
Delays In Diagnosis

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third highest cause of mortality from cancer, largely because of delays in diagnosis. There is currently no effective therapy for advanced stage HCC, although sorafenib, the standard treatment for HCC, systemic therapy (including tyrosine kinase inhibitors and anti-angiogenesis agents), and more recently, immunotherapy, have demonstrated some survival benefit. The measurement and modification of extracellular vesicle (EVs) cargoes—composed of nucleic acids, including miRNAs, proteins, and lipids—holds great promise for future HCC diagnosis, prognosis, and treatment. This review will provide an overview of the most recent findings regarding EVs in HCC, and the possible future use of EVs as “liquid biopsy”-based biomarkers for early diagnosis and as a vehicle for targeted drug-delivery.

Advances in delivery vectors for gene therapy in liver cancer

2020 ◽  
Vol 11 (1) ◽  
pp. 833-850 ◽  
Author(s):  
Katherine E Redd Bowman ◽  
Phong Lu ◽  
Erica R Vander Mause ◽  
Carol S Lim
Keyword(s):  
Hepatocellular Carcinoma ◽  
Gene Therapy ◽  
Viral Vectors ◽  
Gene Editing ◽  
Cancer Death ◽  
Common Cause ◽  
The Third ◽  
Gene Delivery Vectors ◽  
Efficient Delivery ◽  
Therapy Delivery

Hepatocellular carcinoma (HCC) is the third most common cause of cancer death globally, mainly due to lack of effective treatments – a problem that gene therapy is poised to solve. Successful gene therapy requires safe and efficient delivery vectors, and recent advances in both viral and nonviral vectors have made an important impact on HCC gene therapy delivery. This review explores how adenoviral, retroviral and adeno-associated viral vectors have been modified to increase safety and delivery capacity, highlighting studies and clinical trials using these vectors for HCC gene therapy. Nanoparticles, liposomes, exosomes and virosomes are also featured in their roles as HCC gene delivery vectors. Finally, new discoveries in gene editing technology and their impacts on HCC gene therapy are discussed.

Extended Abstract: Management of Liver Cancer

2016 ◽  
Vol 34 (4) ◽  
pp. 438-439 ◽  
Author(s):  
Peter Robert Galle
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Function ◽  
Associated Factors ◽  
Progressive Disease ◽  
Patient Survival ◽  
Western World ◽  
Tumor Treatment ◽  
Common Cause ◽  
The Third ◽  
Liver Cancers

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide. HCC represents more than 90% of primary liver cancers. There is a growing incidence of HCC worldwide. In the Western world, HCC arises in a cirrhotic background in up to 90% of cases, and cirrhosis itself is a progressive disease that affects patient survival. Thus, outcome in patients with HCC and the chances for anti-tumor treatment and its results are dependent not only on tumor-associated factors but also on liver function.

scholarly journals Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma

2020 ◽  
Vol 52 (8) ◽  
pp. 1209-1219 ◽  
Author(s):  
Seo-Young Koo ◽  
Eun-Ji Park ◽  
Chang-Woo Lee
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Immune Responses ◽  
Nonalcoholic Steatohepatitis ◽  
Immune Cell ◽  
Common Cause ◽  
Nonalcoholic Fatty Liver ◽  
Common Cancer ◽  
Aggressive Form ◽  
Immune Cell Subsets

Abstract Nonalcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease, ranges from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH), which is a more aggressive form characterized by hepatocyte injury, inflammation, and fibrosis. Increasing evidence suggests that NASH is a risk factor for hepatocellular carcinoma (HCC), which is the fifth most common cancer worldwide and the second most common cause of cancer-related death. Recent studies support a strong mechanistic link between the NASH microenvironment and HCC development. The liver has a large capacity to remove circulating pathogens and gut-derived microbial compounds. Thus, the liver is a central player in immunoregulation. Altered immune responses are tightly associated with the development of NASH and HCC. The objective of this study was to differentiate the roles of specific immune cell subsets in NASH and HCC pathogenesis.

scholarly journals NF-κB, JNK, and TLR Signaling Pathways in Hepatocarcinogenesis

2010 ◽  
Vol 2010 ◽  
pp. 1-10 ◽  
Author(s):  
Shin Maeda
Keyword(s):  
Hepatocellular Carcinoma ◽  
Signaling Pathways ◽  
Inflammatory Cell ◽  
Prognostic Markers ◽  
Tumor Promotion ◽  
Neoplastic Cell ◽  
Nuclear Factor ◽  
Tlr Signaling ◽  
The Third

Hepatocellular carcinoma (HCC) is the third largest cause of cancer deaths worldwide. The role of molecular changes in HCC have been used to identify prognostic markers and chemopreventive or therapeutic targets. It seems that toll-like receptors (TLRs) as well as the nuclear factor (NF)-κB, and JNK pathways are critical regulators for the production of the cytokines associated with tumor promotion. The cross-talk between an inflammatory cell and a neoplastic cell, which is instigated by the activation of NF-κB and JNKs, is critical for tumor organization. JNKs also regulate cell proliferation and act as oncogenes, making them the main tumor-promoting protein kinases. TLRs play roles in cytokine and hepatomitogen expression mainly in myeloid cells and may promote liver tumorigenesis. A better understanding of these signaling pathways in the liver will help us understand the mechanism of hepatocarcinogenesis and provide a new therapeutic target for HCC.

scholarly journals Platelet counts during pregnancy in Chinese women

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Li-Xia Zhang ◽  
Ning Dong ◽  
Rui-Xia Yang ◽  
Ang Li ◽  
Xuan-Mei Luo ◽  
...  
Keyword(s):  
Chinese Women ◽  
Third Trimester ◽  
Bleeding Events ◽  
Common Cause ◽  
Platelet Counts ◽  
The Third ◽  
Uncomplicated Pregnancy ◽  
Gestational Thrombocytopenia ◽  
The Mean ◽  
Medical University

AbstractObjectivesGestational thrombocytopenia (GT) is the most common cause of thrombocytopenia during pregnancy. However, the occurrence and severity of thrombocytopenia throughout pregnancy in Chinese women are not fully defined.MethodsWe analyzed platelet counts in Chinese women who received prenatal care and/or delivered at the First Affiliated Hospital with Nanjing Medical University between January 2, 2018 and July 19, 2018 in China. These platelet counts were compared with those of nonpregnant women in the same study period.ResultsThe platelet counts of all women continued to decrease significantly each trimester (p < 0.0001). The mean platelet counts of the 818 women who had pregnancy-related complications were lower than those of the 796 women who had uncomplicated pregnancies during the third trimester (p = 0.047). At the time of delivery, platelet counts less than 150 × 109/L were more common in women with pregnancy-related complications than in women with uncomplicated pregnancy (26.7% vs. 19.7%, p = 0.03).ConclusionsPlatelet counts decrease throughout pregnancy in Chinese women and platelet counts less than 150 × 109/L were more common in women with pregnancy-related complications than in women with uncomplicated pregnancy. The pregnant women should be paid more attention for thrombocytopenia to avoid the occurrence of bleeding events.

The Third Generation of Real-Time Virtual Sonography for Navigation in the Treatment of Hepatocellular Carcinoma

2011 ◽  
Vol 37 (8) ◽  
pp. S136
Author(s):  
Y. Eso ◽  
A. Sakamoto ◽  
S.G. Kim ◽  
S. Saito ◽  
H. Nishikawa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Real Time ◽  
Third Generation ◽  
The Third

scholarly journals Prebiotics: A Novel Approach to Treat Hepatocellular Carcinoma

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Naz Fatima ◽  
Tasleem Akhtar ◽  
Nadeem Sheikh
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Antitumor Effect ◽  
Gut Permeability ◽  
Gut Flora ◽  
Effective Barrier ◽  
The Third ◽  
Oncogenic Pathways ◽  
Novel Approach ◽  
Genetic Modifications

Hepatocellular carcinoma is one of the fatal malignancies and is considered as the third leading cause of death. Mutations, genetic modifications, dietary aflatoxins, or impairments in the regulation of oncogenic pathways may bring about liver cancer. An effective barrier against hepatotoxins is offered by gut-liver axis as a change in gut permeability and expanded translocation of lipopolysaccharides triggers the activation of Toll-like receptors which stimulate the process of hepatocarcinogenesis. Prebiotics, nondigestible oligosaccharides, have a pivotal role to play when it comes to inducing an antitumor effect. A healthy gut flora balance is imperative to downregulation of inflammatory cytokines and reducing lipopolysaccharides induced endotoxemia, thus inducing the antitumor effect.

scholarly journals miR-34a Inhibits Cell Proliferation by Targeting SATB2 in Hepatocellular Carcinoma

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Gang Wu ◽  
Zhixi Li ◽  
Youyu Wang ◽  
Xueming Ju ◽  
Rui Huang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Proliferation ◽  
Hepg2 Cells ◽  
Hepatoma Cell ◽  
Luciferase Reporter ◽  
Hepatoma Cell Line ◽  
Novel Therapy ◽  
The Third ◽  
Direct Target

Hepatocellular carcinoma (HCC) is the most common type of malignancy of the liver and has been reported as the third most frequent cause of cancer associated death worldwide. Accumulating evidence showed that the expression of miR-34a was abnormal in HCC patients; however, the role of miR-34a in HCC is not clear. In this study, we have observed low expression of the miR-34a in both HCC tissues and hepatoma cell line as compared to normal control. Further to investigate the role of miR-34a in HCC development, HepG2 cells were transfected with miR-34a mimic. Following transfection, miR-34a expression was significantly increased, which further repressed proliferation of HepG2 cells. Bioinformatics, Luciferase Reporter, RT-qPCR, and western blotting assays indicated that special AT-rich sequence-binding protein-2 (SATB2) is a direct target of miR-34a in HCC cells. There was a negative correlation between the expression levels of SATB2 and miR-34a. Investigation into the molecular mechanism indicated that miR-34a regulated cell proliferation through inhibiting SATB2. Therefore, the results of the present study may improve understanding regarding the role of miR-34a in regulating cell proliferation and contribute to the development of novel therapy of HCC.

Sign in / Sign up

Export Citation Format

Share Document